Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 15/20 | 0.39 |
| ▸ | EED | O75530 | 9/20 | 0.35 |
| ▸ | RBBP4 | Q09028 | 9/20 | 0.35 |
| ▸ | SUZ12 | Q15022 | 9/20 | 0.35 |
| ▸ | AEBP2 | Q6ZN18 | 9/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17515854 | 0.87 | IDO1 (0.41) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL16115163 | 0.84 | IDO1 (0.39) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL17515852 | 0.79 | IDO1 (0.41) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL16114963 | 0.73 | OPRK1 (0.44) | IDO1TP53 | |
| SCHEMBL16115072 | 0.72 | IDO1 (0.39) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL16119857 | 0.69 | TP53 (0.43) | IDO1TP53 | |
| SCHEMBL18111217 | 0.67 | IDO1 (0.39) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL18111223 | 0.66 | IDO1 (0.41) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL16141727 | 0.66 | IDO1 (0.39) | IDO1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL17515848 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533977-B2 | Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same | DONG-A ST CO., LTD. (KR) | 2017-01-03 | — | — | US | disclosed |
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO., LTD. (KR) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CETP, MTTP, APOB | IDO1 2860/4885EZH2 1752/4885EED 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.